It's totally reasonable, say industry analysts. But to the rest of us, it's shocking: California-based Gilead Sciences, maker of antiviral drug and potential COVID-19 treatment remdesivir, said Monday it would charge privately insured Americans $3,120 for a five-day course. Some will pay less, such as patients covered by Medicare or Medicaid and those in other countries. "Outrageous," declared Rep. Lloyd Dogget, arguing that without taxpayers investing $99 million in development, "this drug would have been abandoned." The company, backed by independent analysis, argued that it's a bargain, considering the potential savings of $40,000 in medical care.